Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Treatment of breast cancer
US9517229B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9517229-B2 |
| Application number | US-201214236036-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 27, 2012 |
| Priority date | Jul 29, 2011 |
| Publication date | Dec 13, 2016 |
| Grant date | Dec 13, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating triple negative breast cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of 2. The method of claim 1 , wherein the compound is enzalutamide: 3. The method of claim 1 , wherein the triple negative breast cancer is a subtype selected from the group consisting of basal-like type 1 (BL1), basal-like type 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR) subtypes. 4. The method of claim 1 , wherein cells of the triple negative breast cancer comprise a BRCA1 mutation. 5. The method of claim 1 , wherein the triple negative breast cancer comprises cells that do not express detectable androgen receptor. 6. The method of claim 1 , wherein the triple negative breast cancer comprises cells that express an androgen receptor. 7. The method of claim 1 , further comprising administering to the patient a second therapeutic treatment. 8. The method of claim 3 , wherein the triple negative breast cancer is the BL1 subtype. 9. The method of claim 3 , wherein the triple negative breast cancer is the BL2 subtype. 10. The method of claim 3 , wherein the triple negative breast cancer is the IM subtype. 11. The method of claim 3 , wherein the triple negative breast cancer is the M subtype. 12. The method of claim 3 , wherein the triple negative breast cancer is the MSL subtype. 13. The method of claim 3 , wherein the triple negative breast cancer is the LAR subtype. 14. The method of claim 4 , wherein the compound is enzalutamide. 15. The method of claim 5 , wherein the compound is enzalutamide. 16. The method of claim 6 , wherein the compound is enzalutamide. 17. The method of claim 7 , wherein the compound is enzalutamide. 18. The method of claim 8 , wherein the compound is enzalutamide. 19. The method of claim 9 , wherein the compound is enzalutamide. 20. The method of claim 10 , wherein the compound is enzalutamide. 21. The method of claim 11 , wherein the compound is enzalutamide. 22. The method of claim 12 , wherein the compound is enzalutamide. 23. The method of claim 13 , wherein the compound is enzalutamide.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin · CPC title
- A61K31/4184Primary
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9517229B2 cover?
- The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especiall…
- Who is the assignee on this patent?
- Protter Andrew A, Richer Jennifer, Cochrane Dawn, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4184. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).